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Elevated production of polymeric and monomeric IgAl by the bone
marrow in IgA nephropathy. In bone marrow cultures of 15 patients
with primary IgA nephropathy we found significantly (P = 0.02)
increased synthesis of both monomeric and polymeric IgA I compared
to 23 controls, by using high performance liquid chromatography
(HPLC) fractionation of culture supernatants. The relative contribution
of polymeric to total IgA I produced was not different for the two
groups. Two-color immunofluorescence studies of the percentage of
bone marrow IgAl plasma cells able to bind secretory component in
vitro showed no difference between patients and controls. In the sera of
patients with primary IgA nephropathy the relative contribution of IgAl
polymers to total IgAl was also similar to controls. These results
indicate that in IgA nephropathy, the increased IgA production in the
bone marrow is restricted to the IgA I subclass. The production of both
monomeric and polymeric IgA I is increased in patients during a
quiescent phase of the disease.
Primary IgA nephropathy is characterized by deposits of
IgAl in the glomerular mesangium [1—31. Controversy exists
regarding the relative contribution of IgA polymers in the
deposits. Using immunofluorescence, some investigators find
J-ohain in the mesangial deposits [3—7] and interpret this as
evidence for the presence of IgA polymers. However, others do
not find J-chain [8, 9], or find it only in the presence of 1gM in
the same biopsy [1]. Similarly, conflicting results are reported
for the capacity of the mesangial deposits to bind secretory
component (SC), another technique for demonstrating the pres-
ence of polymeric IgA or 1gM. Whereas some investigators are
able to demonstrate in situ binding to SC [3, 4, 10], others report
negative findings [6, 7]. Elution of mesangial IgA from biopsies
has only been performed in two studies [5, II], and should also
be interpreted with caution in view of the possible in vitro
aggregation of the mesangial IgA by the acid buffer used. Both
elution studies have shown a considerable contribution of large
molecular size IgA in the mesangial deposits.
The amount of polymeric IgA in the circulation of patients
with IgA nephropathy is also controversial: some investigators
find no increase [12—14]; others find an increase with a concom-
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itant increase of monomeric IgA of similar magnitude [8, 15—
18]; and finally, two studies have reported a preferential in-
crease in polymeric IgA, with a higher than normal ratio of
polymeric to total IgA [3, 19].
Our recent findings indicate that the bone marrow is the
production site of the IgA in the mesangium in primary IgA
nephropathy. A significant shift toward the subclass IgAl was
found in the bone marrow of patients [20], with a similar shift in
the circulation [21]. In the present study we investigated the
amounts of polymeric IgAl and monomeric IgAl produced in
the bone marrows of patients with IgA nephropathy, to further
test the hypothesis that the bone marrow is the source of the
mesangial IgA.
Methods
Patients and controls
Bone marrow samples were obtained from the posterior iliac
crest as previously described [20] from 15 patients with biopsy-
proven IgA nephropathy (11 males and 4 females). The mean
age of the patients was 35.5 years (range: 18 to 78). Kidney
function as assessed by serum creatinine levels was normal in
12 patients, 2 patients had mild renal failure (creatinine clear-
ance 48 and 60 mI/mm), and one patient was treated by
hemodialysis. None of the patients had clinical or laboratory
evidence of Henoch Schönlein purpura, systemic lupus erythe-
matosus or liver disease. As controls we used bone marrow
samples obtained from otherwise healthy individuals undergo-
ing lumbar spine surgery (N = 17), or who were serving as
donors for allogeneic bone marrow transplantation (N = 5).
One control was a patient with biopsy-proven mntracapillary
proliferative glomerulonephritis without mesangial deposits of
IgA and normal renal function. The mean age of the controls
was 40.3 years (range: 14 to 59). There were 14 males and 9
females in the control group.
None of the patients or controls in this study had experienced
mucosal infections or episodes of macroscopic hematuria in the
two weeks preceding the study. The patients and controls in
this study include individuals previously studied [20].
Bone marrow culture and immunofluorescence
Bone marrow samples were processed for culture and two
color immunofluorescence as previously described [20]. Culture
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supernatants were stored at —20°C until the high performance
liquid chromatography (HPLC) and SC binding enzyme linked
immunosorbent assay (ELISA) were performed. Bone marrow
cytospins were evaluated with a double immunofluorescence
staining technique to determine the percentage of IgAl plasma
cells producing polymers. The cytospin slides were fixed in
ethanol 95% plus 5% glacial acetic acid for 20 minutes at —20°C.
We used the binding of SC to IgAl plasma cells to determine the
fraction of these cells producing polymers [22]. Human SC was
isolated as previously described [23]. Fixed bone marrow
cytospins were incubated with SC at 200 g/ml for two hours at
room temperature, followed by an overnight incubation at 4°C.
After washing in phosphate buffered saline (PBS), bound SC
was detected with a biotinylated mouse monoclonal antibody to
human SC (NI 194, Nordic Immunological Laboratories, Til-
burg, The Netherlands), followed by streptavidin coupled to
fluorescein isothiocyanate (FITC; Zymed, Sanbio By, Uden,
The Netherlands). Normal mouse IgG (10 gIml) was added in
both the SC and the anti-SC incubations to block non-specific
binding through Fc receptors. The IgAl plasma cells were
stained with a mouse monoclonal antibody to IgAl (NI 69-il,
Nordic) coupled to tetramethylrhodamine isothiocyanate
(TRITC), applied simultaneously with the streptavidin-FITC.
After washing the cytospins in PBS, a drop of glycerol plus
10% PBS, containing 22.5 mg/mI of the anti-fading compound I,
4-diazabicyclo (2,2,2) octane (Sigma Chemical Company, St.
Louis, Missouri, USA) was applied. Counting of fluorescent
cells was performed in a blind fashion by two independent
observers as previously described [20]. SC binding immunoflu-
orescence was found to occur in two distinct patterns: a diffuse
cytoplasmic pattern of staining, and a limited juxtanuclear
pattern. Both patterns were considered as evidence for the
production of polymeric IgA I, and the sum of both patterns was
used in the evaluation. The minimum number of IgAl plasma
cells counted in each individual was 100; in most cases the
number was between 150 and 200. The final results for the
percentage of IgAl plasma cells binding to SC were calculated
as the mean of the results of the two independent observers.
The fraction of bone marrow plasma cells containing IgA
(IgA/Ig: number of IgA plasma cells divided by total number of
plasma cells), and the fraction of IgA plasma cells containing
the subclass IgAl (IgAl/IgA: number of IgAl plasma cells
divided by number of total IgA plasma cells) was measured as
described [20]. The ratio of IgAl containing plasma cells to total
plasma cells (IgAl/Ig) was calculated by multiplying the frac-
tion IgA/Ig with the fraction IgAl/IgA for each individual.
The fraction of IgAl plasma cells binding SC (SClgAl/IgA1)
was measured by dividing the number of SC binding IgAl
plasma cells by the total number of IgAl plasma cells. The
fraction of IgAl plasma cells incapable of binding SC
(SCIgAI/IgAl) was measured by dividing the number of IgAl
plasma cells negative for SC binding by the total number of
IgAl plasma cells. The ratio of SC binding IgAl plasma cells to
total plasma cells (SCIgAl/Ig) was calculated by multiplying
the fraction SCIgAl/IgAl by the fraction IgAl/Ig. The ratio of
non-SC-binding IgAl plasma cells to total plasma cells
(SCIgAI/Ig) was calculated by multiplying the fraction
SCIgAI/IgAl by the fraction IgAl/Ig.
High performance liquid chromatography
The size distribution of the IgAl produced in the bone
marrow cultures was studied using molecular sieving HPLC.
Undiluted culture supernatants were passed through a 0.22 tm
filter (Millipore Corp., Bedford, Massachusetts, USA), and 200
pi of each sample was injected onto a TSK G3000 SW column
connected via a guard column to an HPLC pump (LKB,
Bromma, Sweden). The column was equilibrated and run in 0.1
M phosphate buffer with 0.1 M NaCI, pH 6.8, at a flow rate of 0.3
mI/mm. One minute fractions were collected, and assayed in an
appropriate dilution for IgA content by ELISA as previously
described [20]. Based on the IgA elution profile thus obtained,
fractions were pooled to form a polymeric and a monomeric
pool for each HPLC run. The volumes of each poo1 were
calculated by multiplying the number of fractions with the mean
fraction volume measured in each HPLC run. Concentrations
of IgAl were measured in each polymeric and monomeric pool
using the ELISA previously described [20]. The total contents
of polymeric and monomeric IgAl in each HPLC run were
calculated by multiplying the measured concentration with the
pool volume. The percentage of polymers in each supernatant
was determined by dividing the polymeric content by the sum of
polymeric and monomeric contents.
SC binding ELISA
Polymeric IgA produced in the bone marrow cultures was
also determined in an ELISA measuring SC binding IgA [21].
Briefly, ELISA plates were coated with a mouse monoclonal
antibody to human IgA (NI 184, Nordic). Culture supernatants
were incubated in a serial twofold dilution, followed by human
SC at 12 g/ml. Bound SC was detected with biotinylated
monoclonal anti-SC (NI 194, Nordic), followed by streptavidin
conjugated to horseradish peroxidase, and substrate. Concen-
trations of polymeric IgA present in the supernatants were
calculated from a standard curve using purified human poly-
meric serum IgA.
Measurement of polymeric and monomeric IgAl in serum
In a separate group of patients and controls who participated
in an influenza vaccination study, we measured the serum
concentrations of polymeric and monomeric IgAl. The sera
were obtained 14 days after an intramuscular vaccination with
inactivated influenza virus. The patient group contained 18
individuals with biopsy-proven IgA nephropathy (14 males and
4 females). The mean age of the patients was 36.0 years (range:
24 to 78). Kidney function as assessed by serum creatinine
levels was normal in 13 patients; mild to moderate renal
insufficiency (creatinine clearance 30 to 84 mI/mm) was present
in 5 patients. The control group consisted of 21 healthy hospital
employees, 15 males and 6 females, with a mean age of 32.9
years (range: 24 to 54). Sera were diluted 1:20 with 0.1 M
phosphate buffer with 0.1 M NaCI (pH 6.8), passed through the
0.22 m filter, and run on the HPLC column as described for
the bone marrow culture supernatants. Polymeric and mono-
meric pools were formed as described above, and the concen-
tration of IgAl was measured in each pool. The calculation of
the amount of polymeric and monomeric IgAl, and the percent-
age of polymers present in each diluted serum sample, was
performed as described for the culture supernatants.
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Fig. 1. HPLC size analysis of igAl produced in bone marrow culture
in patients with IgA nephropathy and controls. Polymeric IgA I (pIgA I)
and monomeric IgAl (mIgAl) are expressed as ng per HPLC run.
Horizontal bars denote means.
Statistical analysis
All results are expressed as mean SEM. Differences be-
tween patients and controls were assessed with a Mann Whit-
ney U-test.
Results
Production of IgA polymers in bone marrow culture
Patients with IgA nephropathy produced significantly (P =
0.02) more polymeric IgAl (0.81 0.66 jg per HPLC run) than
controls (0.10 0.01). The production of monomeric IgAl was
also significantly (P = 0.02) higher in patients (0.74 0.42 zg
per HPLC run) than in controls (0.20 0.04). The percentage of
polymeric IgAl produced in the bone marrow cultures was
similar in patients (35.5 5.9%) and controls (38.1 3.3%; P =
0.64; Fig. 1).
The results of the SC binding IgA ELISA are shown in Figure
2. There was no difference in the amount of SC binding IgA
produced by patients (303 58 ng/culture) or controls (342
51; P = 0.57).
Percentage of IgAl plasma cells producing polymers
The observations of the two independent investigators in the
determination of the percentage of IgAl plasma cells binding
SC showed a good correlation (r = 0.84). The percentage of
IgAl plasma cells binding SC was similar in patients (31.6
1.5%) and in controls (31.7 2.5%; P 0.70; Table 1).
Percentage of total plasma cells producing IgAl polymers
The measured fractions of total bone marrow plasma cells
containing IgA (IgA/Ig), IgA plasma cells containing IgAl
(IgAl/IgA), and IgAl plasma cells binding SC (SCIgAl/lgAl)
are given in Table 1. From these data we calculated the ratios
SC41gA1/lg and SCIgAI/!g as described in the Methods
section. Table I shows the mean and SEM of these calculated
Table 1. Immunofluorescence of bone marrow plasma cells
-
Ratioa
IgA
nephropathy Control P
IgA/Ig
IgAl/IgA
IgAl/Ig
SC*lgAl/lgAl
SC1gAl/lg
SCigAI/lg
44.3 2.4
89.7 0.7
39.8 2.2
31.6 1.5
12.6 1.0
27.1 1.5
39.7 2.1
84.3 1.4
33.9 2.1
31.7 2.5
10.9 0.8
24.8 2.0
0.12
0.01
0.04
0.70
0.19
0.30
ratios, and the P values, comparing patients and controls. The
percentage of IgA plasma cells containing the subclass IgAl
was significantly higher in patients than controls (P = 0.01). The
contribution of IgA I plasma cells to the total bone marrow
plasma cell population was also significantly higher in patients
(P 0.04). The ratio SCIgA1/Ig was, however, not increased
in patients.
Polymeric and monomeric IgAl in serum
The serum concentration of monomeric IgAl was signifi-
cantly (P=0.00l) higher in patients (11.36 1.71 g per HPLC
run) than in controls (4.25 0.83 g per HPLC run). The serum
concentration of polymeric IgA I was also higher in patients
(0.30 0.21 g per HPLC run) than in controls (0.07 0.02 g
per HPLC run), but this difference was not statistically signif-
icant (P = 0.13). The calculated ratio of IgAl polymers to total
lgAl in the sera of patients (2.69 l.54%) was not different
compared to controls (1.98 0.39%; P = 0.35).
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Fig. 2. ELISA determination of Sc binding IgA produced in bone
marrow culture in patients with IgA nephropathy and controls. Hori-
zontal bars denote means.
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All data in percent (mean SEM). P values are determined by Mann
Whitney U-test.
a For abbreviations see Methods.
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Discussion
In the HPLC study of bone marrow cultures in patients with
primary IgA nephropathy we find significantly increased syn-
thesis of both polymeric and monomeric IgA I. The ratio of
polymeric IgAl to total IgAl produced was, however, not
different from controls, and this was confirmed in the immuno-
fluorescence study where similar proportions of IgAl plasma
cells capable of binding SC were found in patients and controls.
In patients with IgA nephropathy we find a significant in-
crease in the percentage of bone marrow plasma cells producing
the isotype IgAl. However, if we analyze the contribution of
IgAl plasma cells binding SC, as a marker for polymer produc-
tion, to the total plasma cell population, no increase is found.
The contribution of IgAl plasma cells producing monomers is
also not higher in patients with IgA nephropathy. From these
data it may be concluded that although as a group patients with
IgA nephropathy have an increased bone marrow content of
IgAl plasma cells, this increase is in some patients due to an
increase mainly in monomer-producing cells, and in others to an
increase mainly in polymer-producing cells.
The SC binding IgA produced in the bone marrow cultures
revealed no increase in the production of IgA polymers in
patients with IgA nephropathy. These results may at first seem
contradictory to the significant increase in polymeric IgAl in
the culture supernatants found with the HPLC technique. It
should be noted that in the ELISA determining SC binding
capacity of IgA, as we employed it, inhibition may occur by
monomeric IgA present in the supernatant. Monomeric and
polymeric IgA compete in binding to the anti-IgA coated
surface in such a manner that increased amounts of polymeric
IgA present in the sample may not be detected if increased
amounts of monomeric IgA are also present. In titration exper-
iments using purified monomeric and polymeric IgA standards
this inhibition was indeed found (results not shown). Conse-
quently, the assay measures the relative rather than the abso-
lute amount of polymeric IgA in samples with a wide range of
total IgA concentrations. Although SC binding techniques are
generally considered adequate indicators of polymeric IgA, we
feel the HPLC results to be more reliable in the present study.
Our results in the bone marrow investigation, showing signif-
icant increases in the production of both polymeric and mono-
meric IgAl, with an unaltered ratio of the two, raise the
question whether the sera of patients with IgA nephropathy
show changes compatible with these findings. Our serum data,
obtained in a different set of patients and controls, indeed show
that in primary IgA nephropathy both molecular species of
IgAl, polymeric and monomeric, are increased in the circula-
tion, although the increase is not statistically significant for
polymeric IgAl. The relative contribution of polymeric IgAl to
total IgAl is similar in the sera from patients and controls.
Our serum results confirm the previous findings of other
investigators who studied total IgA in the circulation of patients
with primary IgA nephropathy [8, 15—18], and extend them to
the subclass IgAl. It is this subclass of IgA that is elevated in
the circulation [21] and is preferentially deposited in the mesan-
glum [1—3]. The increase in the serum concentration of mono-
meric IgAl is also in agreement with the reported high content
of monomeric IgAl in the circulating immune complexes in this
disease [24]. Our present results also confirm those obtained in
another recent study in that the increased serum concentration
of polymeric IgA I is accompanied by an increase in monomeric
IgAl of similar magnitude [25]. This results in a calculated
relative contribution of polymers of 0.5 to 2.0% in the circula-
tion of both patients and controls. Although these investigators
employed another technique in the determination of polymeric
IgAl than the HPLC technique used in this study, the percent-
age of IgAl polymers in the sera of patients and controls is
remarkably similar in both studies. The low percentage of
polymeric IgA in the circulation is also in agreement with the
results reported by RadI, Swart and Mestecky [26]. The per-
centage of polymers is considerably lower than previously
reported for healthy individuals using different techniques [8,
15, 17, 19].
The reason for the discrepant results in the literature [3, 8,
12—19, 25] concerning circulating IgA polymers in IgA nephrop-
athy is not clear. The discrepancies may in part be the result of
the many different techniques used in these studies. New data,
however, suggest that the timing of the serum sample, relative
to exacerbations of the disease, may be of greater importance.
In most of the studies no data are given on the clinical state of
the patients at the time of study. Feehally et al [16] recently
reported that in a small series of patients circulating polymeric
IgA was only increased during an active phase of the disease,
and only in some of the patients. This has recently been
confirmed by others [18]. Furthermore, studies of the IgA
immune response have revealed that in the early phases of an
immune response the antigen specific IgA contains a high
proportion of polymers [23, 27—30]. Interestingly, this high
proportion of polymeric IgA is seen not only in mucosal
infections, but equally after systemic immunization [23, 30].
This illustrates that non-mucosal lymphoid organs are also
capable of producing predominantly polymeric IgA antibodies.
The higher proportions of circulating polymeric IgA reported
during macroscopic hematuria [16, 18] may be the result of an
immune response during a recent infection, most often in the
upper respiratory tract. Such a mucosal infection may result in
the production of serum antibodies by the bone marrow through
the existence of a mucosa-bone marrow axis. Evidence for such
an axis, linking mucosa-associated and systemic lymphoid
tissues through the exchange of cells, has been found in
experimental animals [3 1—34].
The findings in the bone marrow and circulation of our
patients were very similar with respect to the increases of both
polymeric and monomeric IgAl, providing further support to
the hypothesis that the mesangial deposits of IgAl are derived
from the bone marrow [20]. The IgA subclass distribution is
significantly different in the bone marrow specimens of patients
with IgA nephropathy compared to healthy controls [20]. The
shift in the IgA subclass distribution toward IgAl is in good
agreement with the similar shift in the circulation [21], and with
the deposition of IgAl in the mesangium [1—3]. The percentage
of IgAl polymers in the circulation and bone marrow of patients
with IgA nephropathy, at least during clinically quiet disease, is
not different from controls. Further studies of the sera and bone
marrow specimens during exacerbations, characterized by mac-
roscopic hematuria, are needed.
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